The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
about
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsCT-P13: design, development, and place in therapyEffectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.Biosimilars and the extrapolation of indications for inflammatory conditions.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.Biosimilar monoclonal antibodies (mAbs) in oncology.ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
P2860
Q26748630-E2CE2E61-96AC-49ED-9E87-BFD173FB5411Q33803728-F2896E18-2A30-4776-A562-2F72564D16FEQ33843746-FBBCB8B7-CDBD-486E-91CA-AABAEEC09DF9Q38932150-6D263A9E-BFF6-4E23-B648-1D98DAF75776Q39016810-5CBD2FCC-7CE7-4323-AC0D-37D5A4A1DA1EQ39018436-34A2136E-16B0-4931-BBC1-4A675036D205Q39359495-E18DC4D1-B66B-4CF6-BBC2-7D80877591FAQ48256716-BC7BE686-6583-4018-82F3-79667FF70D08Q50207250-0901B6D8-7CC2-460D-9346-5E06393C9279Q51280643-6100CE8E-93E7-4A17-88F4-5E2CF2241FF8Q58701964-96DA5C57-C5FC-4148-84F5-A48D1CA5258E
P2860
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The immunogenicity of biosimil ...... e the data across indications?
@ast
The immunogenicity of biosimil ...... e the data across indications?
@en
type
label
The immunogenicity of biosimil ...... e the data across indications?
@ast
The immunogenicity of biosimil ...... e the data across indications?
@en
prefLabel
The immunogenicity of biosimil ...... e the data across indications?
@ast
The immunogenicity of biosimil ...... e the data across indications?
@en
P2093
P2860
P1476
The immunogenicity of biosimil ...... e the data across indications?
@en
P2093
Shomron Ben-Horin
TaekSang Kwon
Tariq Ahmad
Yehuda Chowers
P2860
P356
10.1586/17474124.2015.1091307
P478
P50
P577
2015-09-01T00:00:00Z